By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Halozyme Therapeutics, Inc. 

11388 Sorrento Valley Road

San Diego  California  92121  U.S.A.
Phone: 858-794-8889 Fax: 858-259-2539

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at

Key Statistics

Ownership: Public

Web Site: Halozyme Therapeutics, Inc.
Employees: 152
Symbol: HALO

Company News
Halozyme Therapeutics, Inc. (HALO) Reports Third Quarter 2014 Financial Results 11/11/2014 7:51:17 AM
Halozyme Therapeutics, Inc. (HALO) To Present At The Credit Suisse Healthcare Conference 11/6/2014 7:39:53 AM
Halozyme Therapeutics, Inc. (HALO) To Host Third Quarter 2014 Financial Results Conference Call 11/4/2014 8:16:06 AM
Halozyme Therapeutics, Inc. (HALO) Receives FDA Approval For Additional Manufacturing Facilities For Hylenex┬« Recombinant 10/20/2014 9:03:50 AM
Halozyme Therapeutics, Inc. (HALO) Announces Podium Presentation On PEGPH20 At The New York Academy of Sciences 10/9/2014 9:30:49 AM
Halozyme Therapeutics, Inc. (HALO) Announces Issuance Of U.S. Patent For Companion Diagnostic For PEGPH20 10/7/2014 9:22:34 AM
Halozyme Therapeutics, Inc. (HALO) Receives Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer 10/3/2014 7:29:45 AM
SWOG To Resume Clinical Trial Of Halozyme Therapeutics, Inc. (HALO)'s PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 9/18/2014 10:05:54 AM
FDA Approves Baxter International, Inc. (BAX), Halozyme Therapeutics, Inc. (HALO)'s HYQVIA 9/15/2014 6:15:03 AM
Halozyme Therapeutics, Inc. (HALO)'s PEGPH20 Program In Metastatic Pancreatic Cancer Receives Fast Track Designation 9/3/2014 4:29:03 PM